Skip to main content

12-09-2017 | Metabolic surgery | Review | Article

Metabolic surgery for the treatment of type 2 diabetes in obese individuals

Journal: Diabetologia

Authors: David E. Cummings, Francesco Rubino

Publisher: Springer Berlin Heidelberg


Several bariatric operations originally designed to promote weight loss have been found to powerfully treat type 2 diabetes, causing remission in most cases, through diverse mechanisms additional to the secondary consequences of weight loss. These observations have prompted consideration of such operations as ‘metabolic surgery’, used expressly to treat diabetes, including among patients who are only mildly obese or merely overweight. Large, long-term observational studies consistently demonstrate that bariatric/metabolic surgery is associated with reductions in all cardiovascular risk factors, actual cardiovascular events, microvascular diabetes complications, cancer and death. Numerous recent randomised clinical trials, directly comparing various surgical vs non-surgical interventions for diabetes, uniformly demonstrate the former to be superior for improvements in all glycaemic variables, as well as other metabolic endpoints. These benefits are similar among individuals with type 2 diabetes and a preoperative BMI of 30–35 kg/m2 compared with traditional bariatric surgery patients with a BMI >35 kg/m2. The safety profiles of modern laparoscopic bariatric/metabolic operations are similar to those of elective laparoscopic hysterectomy and knee arthroplasty. However, more evidence regarding the risks, benefits and costs of surgery is needed from very long-term (>5 year) randomised clinical trials powered to observe ‘hard’ clinical endpoints following the operations most commonly used today. Given the efficacy, safety and cost-effectiveness of metabolic surgery, the second Diabetes Surgery Summit (DSS-II) consensus conference recently placed surgery squarely within the overall diabetes treatment algorithm, recommending consideration of this approach for patients with inadequately controlled diabetes and a BMI as low as 30 kg/m2, or 27.5 kg/m2 for Asian individuals. These new guidelines have been formally ratified by 53 leading diabetes and surgery societies worldwide. Given this broad level of endorsement, we feel that the DSS-II recommendations should now replace the outdated National Institutes of Health (NIH) suggestions that have governed bariatric surgery practice and insurance compensation worldwide since 1991.
Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW (2013) Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 368:1613–1624 CrossRefPubMed
Rubino F, Nathan DM, Eckel RH et al (2016) Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 39:861–877 CrossRefPubMed
American Diabetes Association (2017) Obesity management for the treatment of type 2 diabetes. Diabetes Care 40:S57–S63 CrossRef
Batterham RL, Cummings DE (2016) Mechanisms of diabetes improvement following bariatric/metabolic surgery. Diabetes Care 39:893–901 CrossRefPubMed
Schauer PR, Mingrone G, Ikramuddin S, Wolfe B (2016) Clinical outcomes of metabolic surgery: efficacy of glycaemic control, weight loss, and remission of diabetes. Diabetes Care 39:902–911 CrossRefPubMed
Arterburn D, Bogart A, Sherwood N et al (2013) A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 23:93–102 CrossRefPubMedPubMedCentral
Holman RR, Paul SK, Bethel MA et al (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589 CrossRefPubMed
Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653 CrossRefPubMed
Sjostrom L (2013) Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med 273:219–234 CrossRefPubMed
Adams TD, Davidson LE, Litwin SE et al (2012) Health benefits of gastric bypass surgery after 6 years. JAMA 308:1122–1131 CrossRefPubMedPubMedCentral
Arterburn DE, Olsen MK, Smith VA et al (2015) Association between bariatric surgery and long-term survival. JAMA 313:62–70 CrossRefPubMed
Adams TD, Arterburn DE, Nathan DM, Eckel RH (2016) Clinical outcomes of metabolic surgery: microvascular and macrovasular complications. Diabetes Care 39:912–923 CrossRefPubMedPubMedCentral
Thaler JP, Cummings DE (2009) Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 150:2518–2525 CrossRefPubMed
Cummings DE, Cohen RV (2016) Bariatric/metabolic surgery to treat type 2 diabetes in patients with a BMI <35 kg/m 2. Diabetes Care 39:924–933 CrossRefPubMedPubMedCentral
Cummings DE, Cohen RV (2014) Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol 2:175–181 CrossRefPubMedPubMedCentral
Sjostrom L, Narbro K, Sjostrom CD et al (2007) Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357:741–752 CrossRefPubMed
Adams TD, Gress RE, Smith SC et al (2007) Long-term mortality after gastric bypass surgery. N Engl J Med 357:753–761 CrossRefPubMed
Vest AR, Heneghan HM, Agarwal S, Schauer PR, Young JB (2012) Bariatric surgery and cardiovascular outcomes: a systematic review. Heart 98:1763–1777 CrossRefPubMed
Panunzi S, De Gaetano A, Carnicelli A, Mingrone G (2015) Predictors of remission of diabetes mellitus in severely obese individuals undergoing bariatric surgery: do BMI or procedure choice matter? A meta-analysis. Ann Surg 261:459–467 CrossRefPubMed
Maglione MA, Gibbons MM, Livhits M, et al (2013) Bariatric surgery and non-surgical therapy in adults with metabolic conditions and a body mass index of 30.0 to 34.9 kg/m2. AHRQ Comparative Effectiveness Reviews, No. 82. Available from www.​ncbi.​nlm.​nih.​gov/​books/​NBK148685/​. Accessed 9 October 2017
Consensus Development Conference Panel (1991) Gastrointestinal surgery for severe obesity. Ann Intern Med 115:956–961 CrossRef
Flum DR, Belle SH, King WC et al (2009) Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 361:445–454 CrossRefPubMed
Aminian A, Brethauer SA, Kirwan JP, Kashyap SR, Burguera B, Schauer PR (2015) How safe is metabolic/diabetes surgery? Diabetes Obes Metab 17:198–201 CrossRefPubMed
Picot J, Jones J, Colquitt JL et al (2009) The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 13:1–190 CrossRef
Keating C, Neovius M, Sjoholm K et al (2015) Health-care costs over 15 years after bariatric surgery for patients with different baseline glucose status: results from the Swedish Obese Subjects study. Lancet Diabetes Endocrinol 3:855–865 CrossRefPubMedPubMedCentral
CDC Diabetes Cost-Effectiveness Group (2002) Cost-effectiveness of intensive glycaemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287:2542–2551 CrossRef
Rubino R, Kaplan LM, Schauer PR, Cummings DE (2010) The Diabetes Surgery Summit Consensus Conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg 251:399–405 CrossRefPubMed
Rubino F, Schauer PR, Kaplan LM, Cummings DE (2010) Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med 61:393–411 CrossRefPubMed
Lee WJ, Wang W, Lee YC, Huang MT, Ser KH, Chen JC (2008) Effect of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BMI >35 and <35 kg/m 2. J Gastrointest Surg 12:945–952 CrossRefPubMed